This blog tracks updates to the Blood Sugar 101 Web site.


Tuesday, April 12, 2011

Huge Long-Term Study: Glibenclimide, Glipizide, Glimipiride, and Tolbutamide Associated with Increased Risk of Death and Heart Attack.

Page Changed Amaryl, Glyburide, Prandin, Starlix: Drugs that Stimulate Insulin Secretion

Added this text:

Then in 2011, a study analyzed the health records of "All Danish residents >20 years, initiating single-agent I[nsulin] S[ecretogogues, ie. Sulfs and glinides] or metformin between 1997 and 2006 were followed for up to 9 years (median 3.3 years)." It found the following drugs were as safe as Metformin: Prandin (repaglinide), and Diamicron (gliclazide, not sold in the U.S.).

All the other sulfonylurea drugs raised the risk of death, whether or not people had had a heart attack before taking them. The study concludes:
Monotherapy with the most used I[nsulin]S[ecretagogues]s, including glimepiride, glibenclamide, glipizide, and tolbutamide, seems to be associated with increased mortality and cardiovascular risk compared with metformin. Gliclazide and repaglinide appear to be associated with a lower risk than other I[nsulin]S[ecretagogues]s.
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Tina Ken Schramm et al. Eur Heart J (2011) doi: 10.1093/eurheartj/ehr077

No comments: